Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
January 4, 2007

Affinium Awarded $4.8M Biodefense Contract

  • Affinium Pharmaceuticals executed a $4.8-million contract with the Defense Threat Reduction Agency (DTRA) to aid its research, which has relevance to potential biological warfare and bioterrorism agent.

    The two-year contract will fund preclinical studies of selected compounds from Affinium's fatty acid biosynthesis inhibitor portfolio that have demonstrated potential as therapeutics for the treatment of diseases caused by serious pathogens including Francisella tularensis.

    Under the contract, Affinium will investigate the properties of a select group of its compounds. Following these initial investigations, the company and its partners will conduct microdosing studies to characterize the compounds' human pharmacokinetic properties and select a lead development candidate to undergo IND-enabling preclinical development as an oral tularemia therapeutic.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.